These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 8794806)

  • 1. Immunogenicity and safety of recombinant Helicobacter pylori urease in a nonhuman primate.
    Stadtländer CT; Gangemi JD; Khanolkar SS; Kitsos CM; Farris HE; Fulton LK; Hill JE; Huntington FK; Lee CK; Monath TP
    Dig Dis Sci; 1996 Sep; 41(9):1853-62. PubMed ID: 8794806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The mucosal adjuvanticity of two nontoxic mutants of Escherichia coli heat-labile enterotoxin varies with immunization routes.
    Park EJ; Chang JH; Kim JS; Yum JS; Chung SI
    Exp Mol Med; 2000 Jun; 32(2):72-8. PubMed ID: 10926118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Parenteral adjuvant activities of Escherichia coli heat-labile toxin and its B subunit for immunization of mice against gastric Helicobacter pylori infection.
    Weltzin R; Guy B; Thomas WD; Giannasca PJ; Monath TP
    Infect Immun; 2000 May; 68(5):2775-82. PubMed ID: 10768972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral immunization with urease and Escherichia coli heat-labile enterotoxin is safe and immunogenic in Helicobacter pylori-infected adults.
    Michetti P; Kreiss C; Kotloff KL; Porta N; Blanco JL; Bachmann D; Herranz M; Saldinger PF; Corthésy-Theulaz I; Losonsky G; Nichols R; Simon J; Stolte M; Ackerman S; Monath TP; Blum AL
    Gastroenterology; 1999 Apr; 116(4):804-12. PubMed ID: 10092302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of low dose Escherichia coli enterotoxin adjuvant for urease based oral immunisation against Helicobacter pylori in healthy volunteers.
    Banerjee S; Medina-Fatimi A; Nichols R; Tendler D; Michetti M; Simon J; Kelly CP; Monath TP; Michetti P
    Gut; 2002 Nov; 51(5):634-40. PubMed ID: 12377799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of E coli enterotoxin adjuvant for urease-based rectal immunization against Helicobacter pylori.
    Sougioultzis S; Lee CK; Alsahli M; Banerjee S; Cadoz M; Schrader R; Guy B; Bedford P; Monath TP; Kelly CP; Michetti P
    Vaccine; 2002 Dec; 21(3-4):194-201. PubMed ID: 12450694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunization with recombinant Helicobacter pylori urease decreases colonization levels following experimental infection of rhesus monkeys.
    Lee CK; Soike K; Hill J; Georgakopoulos K; Tibbitts T; Ingrassia J; Gray H; Boden J; Kleanthous H; Giannasca P; Ermak T; Weltzin R; Blanchard J; Monath TP
    Vaccine; 1999 Mar; 17(11-12):1493-505. PubMed ID: 10195786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of oral immunization with recombinant urease on murine Helicobacter felis gastritis.
    Pappo J; Thomas WD; Kabok Z; Taylor NS; Murphy JC; Fox JG
    Infect Immun; 1995 Apr; 63(4):1246-52. PubMed ID: 7890380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Immunopotency of the recombinant urease B subunit vaccine of Helicobacter pylori after intranasal administration to mice].
    Gao ZG; Zou QM; Guo G; Guo TS; Zou QM; Zeng WK; Xie QH
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2003 Jan; 19(1):68-70. PubMed ID: 15132912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral immunization with recombinant Helicobacter pylori urease confers long-lasting immunity against Helicobacter felis infection.
    Myers GA; Ermak TH; Georgakopoulos K; Tibbitts T; Ingrassia J; Gray H; Kleanthous H; Lee CK; Monath TP
    Vaccine; 1999 Mar; 17(11-12):1394-403. PubMed ID: 10195775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the adjuvant effect of Escherichia coli heat-labile enterotoxin mutant (LTK63) on the systemic immune responses to intranasally co-administered measles virus nucleoprotein. Part I: antibody responses.
    Erume J; Partidos H
    Afr Health Sci; 2001 Aug; 1(1):3-8. PubMed ID: 12789125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel intranasal immunization techniques for antibody induction and protection of mice against gastric Helicobacter felis infection.
    Weltzin R; Kleanthous H; Guirakhoo F; Monath TP; Lee CK
    Vaccine; 1997 Mar; 15(4):370-6. PubMed ID: 9141207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccination against Helicobacter pylori in non-human primate models and humans.
    Lee CK
    Scand J Immunol; 2001 May; 53(5):437-42. PubMed ID: 11309150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunization against natural Helicobacter pylori infection in nonhuman primates.
    Dubois A; Lee CK; Fiala N; Kleanthous H; Mehlman PT; Monath T
    Infect Immun; 1998 Sep; 66(9):4340-6. PubMed ID: 9712786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distinctive immunomodulatory and inflammatory properties of the Escherichia coli type II heat-labile enterotoxin LT-IIa and its B pentamer following intradermal administration.
    Mathias-Santos C; Rodrigues JF; Sbrogio-Almeida ME; Connell TD; Ferreira LC
    Clin Vaccine Immunol; 2011 Aug; 18(8):1243-51. PubMed ID: 21677110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The New World primate, Aotus nancymae, as a model for examining the immunogenicity of a prototype enterotoxigenic Escherichia coli subunit vaccine.
    Jones FR; Hall ER; Tribble D; Savarino SJ; Cassels FJ; Porter C; Meza R; Nunez G; Espinoza N; Salazar M; Luckett R; Scott D
    Vaccine; 2006 May; 24(18):3786-92. PubMed ID: 16343702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mucosal immunogenicity of the Escherichia coli heat-labile enterotoxin: role of the A subunit.
    de Haan L; Holtrop M; Verweij WR; Agsteribbe E; Wilschut J
    Vaccine; 1996 Mar; 14(4):260-6. PubMed ID: 8744549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and preclinical evaluation of safety and immunogenicity of an oral ETEC vaccine containing inactivated E. coli bacteria overexpressing colonization factors CFA/I, CS3, CS5 and CS6 combined with a hybrid LT/CT B subunit antigen, administered alone and together with dmLT adjuvant.
    Holmgren J; Bourgeois L; Carlin N; Clements J; Gustafsson B; Lundgren A; Nygren E; Tobias J; Walker R; Svennerholm AM
    Vaccine; 2013 May; 31(20):2457-64. PubMed ID: 23541621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative analysis of the mucosal adjuvanticity of the type II heat-labile enterotoxins LT-IIa and LT-IIb.
    Martin M; Metzger DJ; Michalek SM; Connell TD; Russell MW
    Infect Immun; 2000 Jan; 68(1):281-7. PubMed ID: 10603399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms for mucosal immunogenicity and adjuvancy of Escherichia coli labile enterotoxin.
    Takahashi I; Marinaro M; Kiyono H; Jackson RJ; Nakagawa I; Fujihashi K; Hamada S; Clements JD; Bost KL; McGhee JR
    J Infect Dis; 1996 Mar; 173(3):627-35. PubMed ID: 8627026
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.